Semaglutide vs Tirzepatide: Which One Fits You

One Receptor or Two

Start with what the two molecules have in common, because it is most of the story. Both are synthetic peptides built to resemble incretins, the gut hormones released after a meal that tell the pancreas to secrete insulin and tell the brain the meal is landing. Both are modified so they survive in the bloodstream for about a week instead of a few minutes, which is why each is a once-weekly injection. Both slow how fast the stomach empties and reduce appetite through receptors in the brainstem and hypothalamus. Anyone who has taken either drug recognizes the felt result: food noise goes quiet, portions shrink without effort, and a plate that used to look normal looks like too much.

The difference is the receptor count. Semaglutide is a GLP-1 receptor agonist and nothing else. Tirzepatide was engineered to activate two receptors at once: GLP-1 and GIP, the glucose-dependent insulinotropic polypeptide receptor. GIP is the other major incretin, and for years it was considered a dead end for obesity drugs because people with type 2 diabetes respond poorly to it on its own. The tirzepatide design bet was that GIP activity layered on top of GLP-1 activity would do something neither did alone. Nauck and D'Alessio's 2022 review in Cardiovascular Diabetology walks through the pharmacology: the molecule is a 39-amino-acid peptide on a GIP backbone, acylated with a fatty acid chain to bind albumin, with roughly five-fold higher affinity for the GIP receptor than the GLP-1 receptor.

Nauck MA, D'Alessio DA. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction." Cardiovascular Diabetology, 2022. PMID 36050763. View study

What GIP adds in a human being is still argued about. In rodents it reduces food intake on its own. In people that has not been cleanly shown, and the same review is candid that the mechanism of the second receptor remains an open question. The leading hypotheses involve effects on fat tissue, insulin sensitivity, and possibly a dampening of the nausea that pure GLP-1 stimulation produces. Hold that uncertainty in mind. It matters later, because "two receptors is better than one" is a marketing sentence, not a mechanism, and the honest version is "two receptors produced larger average weight loss in trials of the approved drug, for reasons that are only partly understood."

What the FDA Labels Say

The cleanest public facts about either molecule live in the FDA-approved prescribing information for the branded products, so that is where a comparison should start. As of August 2026 the Wegovy label (revised June 2026) lists four indications for the injection: reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; weight reduction and long-term maintenance in adults and adolescents 12 and older with obesity, or adults with overweight plus a weight-related condition; and, under accelerated approval, treatment of noncirrhotic MASH with moderate to advanced liver fibrosis. The Zepbound label (revised April 2026) lists two: weight reduction and maintenance in the same adult obesity and overweight populations, and moderate to severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro carry the type 2 diabetes indications for each molecule.

The dose ladders are different shapes. Wegovy starts at 0.25 mg once weekly for four weeks, then 0.5 mg, 1 mg, and 1.7 mg for four weeks each, reaching the recommended 2.4 mg maintenance dose at week 17. Patients who tolerate 2.4 mg for at least four weeks and need further weight reduction may go to a 7.2 mg maximum, a dose added to the label in 2025. Zepbound starts at 2.5 mg once weekly for four weeks, increases to 5 mg, then rises in 2.5 mg increments no faster than every four weeks, with maintenance at 5, 10, or 15 mg and a 15 mg ceiling. The milligram numbers are not comparable across drugs; a 2.4 mg semaglutide dose and a 15 mg tirzepatide dose are both "top of the ladder" for their molecule.

Wegovy (semaglutide) injection, U.S. Prescribing Information, Novo Nordisk. Revised 06/2026. Zepbound (tirzepatide) injection, U.S. Prescribing Information, Eli Lilly. Revised 04/2026, via DailyMed. View study

One label detail gets skipped in most comparisons and should not be. Both labels say the escalation schedule exists to reduce gastrointestinal reactions, and both allow a pause: if a patient does not tolerate a step, the label suggests holding at the current dose for another four weeks rather than pushing on. The ladder is a ceiling on speed, not a schedule you are obligated to keep. That framing carries directly into how PeRx runs each 28-day cycle, covered below.

The Head-to-Head Research, Labeled Honestly

The question everyone actually types is "which one works better," and the literature has a consistent answer about the approved drugs. We will give it plainly and then be equally plain about what it does not cover.

Munawar and colleagues published a systematic review and meta-analysis in Cureus in 2025 that pooled seven direct comparisons, two randomized trials and five observational studies, totaling 28,980 adults with overweight or obesity. Tirzepatide produced greater weight loss than semaglutide, with a standardized mean difference of 0.75 in its favor and higher odds of reaching a 10 percent reduction in body weight. A separate 2025 meta-analysis by Wen and colleagues in Endocrinology, Diabetes and Metabolism looked only at patients with type 2 diabetes across four direct-comparison studies of 28,827 people and found a mean difference of about 4.8 kg favoring tirzepatide, with average reductions of roughly 11 percent versus 7 percent of body weight. The pattern is the same in every pooled analysis we could find: on average, the dual agonist moves the scale more.

Munawar N et al. "Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies." Cureus, 2025. PMID 40666599. View study

Wen J et al. "Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies." Endocrinology, Diabetes and Metabolism, 2025. PMID 40184508. View study

Two caveats from inside the studies themselves. The Munawar pooled estimate leans on observational data, where the people prescribed tirzepatide may have differed from those prescribed semaglutide in ways the statistics cannot fully correct. And most comparisons ran less than a year, so they say little about what happens at maintenance, a topic our guide on GLP-1 maintenance dosing Read nextGLP-1 Maintenance and Microdosing After Goal WeightReach your goal weight on semaglutide or tirzepatide and the advice splits in two. The label and most medical sites say stay on your full dose indefinitely. Half of Reddit says stretch it to every ten days or shrink it to a fraction, and nobody with a prescription pad seems willing to discuss either. This page discusses both: what people actually do in maintenance, what the pharmacology and the real-world data say about each path, and why every one of these changes belongs on a prescription rather than in a spreadsheet.Read article takes up separately. The honest summary: tirzepatide has the stronger average efficacy signal in approved-drug research, the gap is real but not universal, and it costs more. Whether that trade is worth it for a particular person is a prescribing question, which is the rest of this page.

Side-Effect Profiles Compared

The side-effect story is more alike than different. Both labels list the same cluster at the top: nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia, concentrated during dose escalation and easing for most people once a dose has been held for a few weeks. Both carry identical boxed warnings about thyroid C-cell tumors seen in rodents, and identical warnings about pancreatitis, gallbladder disease, acute kidney injury from dehydration after severe vomiting or diarrhea, hypoglycemia when combined with insulin or a sulfonylurea, and delayed gastric emptying that can change how other oral medications are absorbed.

Where the two diverge, the published comparisons point in two directions. Xie and colleagues, in a 2025 systematic review in Diabetes, Metabolic Syndrome and Obesity, compared GIP/GLP-1 co-agonists against single GLP-1 agonists for weight management and found no significant difference in serious adverse events. Tirzepatide showed a lower rate of diarrhea in that analysis, while GLP-1 mono-agonists reported more abdominal pain and dyspepsia. In the other direction, tirzepatide had a markedly higher rate of injection site reactions than semaglutide, which fits the label figures of 6 to 8 percent for Zepbound. And the Munawar review noted that tirzepatide discontinuation for adverse events in its randomized comparisons ran 4.3 to 7.1 percent, which is not trivial for a drug meant to be taken for years.

Xie Z et al. "Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review." Diabetes, Metabolic Syndrome and Obesity, 2025. PMID 40821754. View study

The label nausea numbers deserve a second look because they are often quoted as proof tirzepatide is gentler. Wegovy 2.4 mg reported nausea in 44 percent of patients versus 16 percent on placebo; Zepbound reported 25 to 29 percent across doses. Those came from different trials with different populations and different escalation schedules, and a cross-trial comparison of two percentages is not a head-to-head. What can be said is that neither drug is nausea-free, that the first few weeks on any new dose step are the hard part for both, and that patients who had a rough experience on one molecule do not reliably have the same experience on the other. Sleep changes, which come up more with tirzepatide in patient forums, get their own treatment in our piece on tirzepatide and insomnia Read nextTirzepatide Insomnia: Why GLP-1s Disrupt SleepYou started tirzepatide, the weight is moving, and now you are staring at the ceiling at 3 AM wondering whether the shot did this. The internet offers two contradictory answers. One says this drug family treats sleep apnea, which is true. The other is a wall of forum posts from people who suddenly cannot sleep on it, which is also real. Nobody ranking for this search explains both sides. This page does: what the trials and labels actually say, why a subset of GLP-1 users genuinely does sleep worse, and what to change this week.Read article .

One difference is purely practical. Because tirzepatide is dosed in larger milligram amounts, the injected volume from a compounded vial at a given concentration can be larger, and injection site reactions are more common with it. Rotating sites matters more than people expect. The abdomen, thigh, and upper arm all work; our guide on where to inject semaglutide and tirzepatide Read nextWhere to Inject Semaglutide and TirzepatideBoth are once-weekly subcutaneous injections, and the three standard sites are the same for each. The part that trips people up is not the site. It is that a compounded vial is not a prefilled pen, so you are drawing your own dose and reading it in syringe units. Here is the practical version.Read article covers rotation patterns and the two-inch rule around the navel.

Why Tirzepatide Costs $150 More

PeRx's price is $249 per 28-day cycle for compounded semaglutide with B12 and $399 for compounded tirzepatide with B12. The $150 gap is not a margin decision; it tracks the cost of the active ingredient. Tirzepatide is a longer, more complex peptide to synthesize, its weekly doses are measured in milligrams rather than fractions of a milligram, and the pharmaceutical-grade API costs the pharmacy considerably more per vial. A patient at 15 mg per week is receiving roughly six times the mass of drug that a semaglutide patient at 2.4 mg receives. The pharmacy's cost scales with that, and so does ours.

For context, the branded pens list near or above a thousand dollars a month before discounts, and manufacturer cash-pay programs for the weight indications have moved around a great deal since 2025. We do not track those prices here because they change monthly. The point of the comparison is only that the compounded route is a different tier of product at a different price, and the honest per-month math for each tier, including the gray market, is in gray-market GLP-1s vs compounded Read nextGray-Market GLP-1s vs Compounded: What Testing MissesThis page is for the person doing spreadsheet math on a $44 internet vial versus a legitimate prescription. No moralizing and no scare quotes. What the three tiers of GLP-1 supply legally are, what a certificate of analysis actually proves, what it cannot, and what each route really costs per month.Read article .

The budgeting question most people skip is the one-year total. Twelve cycles of semaglutide at PeRx is $2,988; twelve cycles of tirzepatide is $4,788. That $1,800 difference is the real number to weigh against the average efficacy gap in approved-drug trials. For some patients that trade is obviously worth it. For others, particularly those with modest weight goals, a good response to semaglutide would make the extra spend pointless. Which brings us to how a prescriber actually thinks about it.

What a Prescriber Weighs

There is no algorithm that maps a patient to a molecule, and anyone selling one is selling. What exists is a set of questions that a licensed provider reviewing a PeRx intake works through, usually in something like this order. Nothing below is a rule and none of it substitutes for that review. It is offered so you know what the review is looking at and can answer the intake accurately.

Have you taken a GLP-1 before, and what happened? This is the single most informative question. A patient who did well on semaglutide and stopped for cost or supply reasons has a known-good option and rarely needs to change molecules. A patient who plateaued on semaglutide at its full dose for several months is the classic case where a switch to the dual agonist is discussed. A patient who could not tolerate semaglutide's nausea at any step is a more complicated conversation: the second molecule might be gentler for them, or the problem might have been escalation speed rather than the drug.

What are the contraindications and cautions? Both molecules share a hard stop: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both are avoided in pregnancy and in anyone planning one; the Wegovy label advises stopping at least two months before a planned pregnancy because of semaglutide's long half-life. A history of pancreatitis, gastroparesis, or severe gastrointestinal disease is a caution for both. Neither molecule is favored over the other on these grounds; they are threshold questions that decide whether either drug is appropriate at all. Our overview of what providers review before prescribing Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. Here is the checklist they run from the other side of the screen: the conditions that change whether a peptide is safe, the medications that get cross-checked, and what gets escalated or declined.Read article covers the general screening.

What else are you taking? Insulin and sulfonylureas raise hypoglycemia risk with either drug. Oral medications with a narrow therapeutic window, including some thyroid replacement and oral contraceptives, can be affected by delayed gastric emptying with both. The Zepbound label specifically advises a backup non-oral contraceptive for four weeks after starting and after each dose increase. That is a tirzepatide-specific label instruction and it matters for a meaningful share of patients.

How much weight, and how fast? A patient with a large amount of weight to lose, or with weight-related conditions such as sleep apnea that make the size of the effect clinically important, is more likely to have the dual agonist discussed as the starting molecule. A patient whose goal is fifteen pounds and a quieter relationship with food is often well served by semaglutide, and the $1,800 annual difference buys nothing they need. The how we approach weight-loss peptides Read nextHow We Approach Weight-Loss PeptidesWeight-loss peptides do a narrower job than a GLP-1: instead of suppressing appetite, they protect lean mass, target visceral fat, and improve how your cells burn fuel. Here is how a provider decides which one fits, and where peptides are oversold.Read article page describes the overall philosophy.

What is the budget over a year, not a month? Providers ask this because the failure mode they see most is a patient who starts on the more expensive option, cannot sustain it, and stops entirely at month four. A drug you can stay on at a dose you tolerate beats a drug you cannot afford by month six. This is a legitimate clinical input, not a sales consideration, and it is why we quote the annual figures above.

Switching Between Them

Switching is common and in both directions. The semaglutide-to-tirzepatide switch usually follows a plateau at full dose or a specific reason to want the second receptor. The tirzepatide-to-semaglutide switch is usually about cost, injection site reactions, or a patient who has reached goal weight and wants a less expensive maintenance option. Neither switch is a failure of the first drug.

Two facts about switching that surprise people. First, there is no milligram conversion. Because the molecules act on different receptors with different potencies, a patient at 2.4 mg of semaglutide does not step across to some "equivalent" tirzepatide dose. Prescribers generally restart the second molecule at or near its own starting step and escalate from there, and the same in reverse. The label ladders above are the framework; how quickly a given patient climbs is a clinical judgment. Second, there is a timing gap. Both drugs have roughly week-long half-lives, so the switch normally happens at the point the next weekly dose was due, with the old drug simply not taken again, and some prescribers hold a week between the last dose of one and the first dose of the other.

Expect the first weeks on the new molecule to feel like starting over, because pharmacologically that is what is happening. The nausea window reopens even for a patient who had been comfortable at full dose for a year. Patients switching to tirzepatide sometimes assume they can skip the 2.5 mg step because they are "experienced"; the Zepbound label calls 2.5 mg an initiation dose that is not intended for maintenance, and it exists precisely to let the body adapt. At PeRx, a switch means a new prescription and a new subscription for the other SKU, with the same 28-day cycle and provider review.

How Both Work at PeRx

The mechanics are identical for the two drugs, which is deliberate. You complete an online intake covering history, medications, and goals. A licensed provider reviews it; PeRx prescribes by telehealth in all 50 states. Your card is saved at checkout but not charged unless the provider approves. If approved, the prescription goes to a US 503A compounding pharmacy, which prepares your vial and ships it FedEx overnight in cold packaging with syringes and swabs. The vial arrives fully reconstituted and ready to use. You inject once weekly under the skin.

The subscription is one vial per 28 days, and that number is not arbitrary. A GLP-1 vial is four weekly doses; billing on 30 days would leave patients a week short once review and shipping are counted. Each vial is filled at one concentration, and the provider sets that strength on each cycle's approval. That is why PeRx will not ship three months at once: the second and third vials would be at a dose nobody had yet approved you for. It is also why there is no dose picker at checkout. You buy the medication; the strength is a clinical variable.

Before each renewal you receive an advance notice by email that says what will be charged and when, with a link to cancel. Cancellation is a single click from your account, no phone call and no retention screen, because federal and state law require cancelling to be at least as easy as signing up and because we would rather keep patients than trap them. A short check-in accompanies each renewal so the prescriber has the weight and tolerance information described above.

Both drugs are compounded with vitamin B12 in the same vial. B12 is a common additive in compounded GLP-1 preparations. We make no claim that it changes how the drug works or how it feels, and you should be skeptical of any clinic that does. Sublingual versions of both molecules are in development at PeRx but are not available as of August 2026.

Many patients on either GLP-1 also ask about pairing it with other peptides for muscle preservation, energy, or recovery. That is a separate decision with its own trade-offs, covered in peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article . The product pages for compounded semaglutide and compounded tirzepatide carry the current availability and the intake link.

Common Questions